Henrijette Richter
Managing Partner, Sofinnova Partners
Henrijette Richter is a Managing Partner at Sofinnova Partners and a key member of the Sofinnova Capital Strategy team, the firm’s flagship early-stage biotech and medtech fund, which recently closed its 11th vintage at $650 million.
Since joining Sofinnova in 2014, she has led and supported investments across a portfolio of high-impact life science companies, including NanoPhoria Bioscience, HAYA Therapeutics, Mozart Therapeutics, Freya Biosciences, Muna Therapeutics, NodThera, and Delinia (acquired by Celgene).
Before Sofinnova, Henrijette helped build Novo Seeds from the ground up, joining at its founding in 2007. As Investment Director, she played a central role in creating, financing, and scaling several successful ventures such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, and EpiTherapeutics (acquired by Gilead). Her venture career began more than two decades ago at Sunstone Capital, following a postdoctoral fellowship at the MIT Center for Cancer Research.
Henrijette is recognized for her strategic insight and contributions across the European biotech ecosystem. She serves on the SUND Advisory Board at the University of Copenhagen and the Sanger Venture Advisory Group where she helps shape policy and guide innovation across the sector.
She holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S, and completed her postdoctoral training at MIT. Henrijette brings deep scientific expertise, sharp investment acumen, and a long-standing commitment to advancing breakthrough science into transformative companies.
Henrijette started her career in venture more than 20 years ago when she joined Sunstone Capital from her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Henrijette is part of several advisory boards including the SUND Advisory Board (University of Copenhagen), The Sanger Venture Advisory Group, and is part of the Invest Europe VC Council.
Henrijette holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.
“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”
Sectors
Biopharmaceuticals & Medical Devices
